INSIGHTEC#s Exablate Neuro Named Best Medical Technology at Esteemed Prix Galien Awards 2017

Food and Healthcare Press Releases Monday October 30, 2017 09:00
HAIFA, Israel--30 Oct--PRNewswire/InfoQuest

INSIGHTEC , the leader in MR-guided Focused Ultrasound (MRgFUS), has been awarded Best Medical Technology for Exablate Neuro by The Galien Foundation.   Exablate Neuro is an innovative medical technology that uses focused ultrasound coupled with MR imaging (MRgFUS), to precisely target and treat areas deep within the brain through an intact skull.

The prestigious Prix Galien awards recognize excellence in scientific innovations that improve the state of human health. The Best Medical Technology award confirms INSIGHTEC's vision of transformative healthcare and the company's determination to improve the daily lives of patients living with essential tremor.

"It's a great honor to receive this award, which recognizes our dedication to researching and developing a non-invasive medical treatment," said INSIGHTEC's CEO and Chairman of the Board, Maurice R. Ferre MD. "Our pursuit of innovation is not only driven by our founder Kobi Vortman, but also by the leading neurosurgery centers which have adopted the Exablate Neuro around the world. This is an exciting time for INSIGHTEC and spurs on our commitment to supporting healthcare professionals, deliver treatments which truly improve the lives of people worldwide."

Having accepted the award at The American Museum of Natural History in New York City, INSIGHTEC's Vice President of Marketing, Xen Mendelsohn Aderka added "To be seen as an innovator whilst in the presence of so many renowned figures in the pharmaceutical, biomedical and medical technology industry, is a great accolade. We thank the judges for acknowledging the hard work and dedication of our team."

The U.S. Food and Drug Administration (FDA) approved Exablate Neuro in July 2016 for the non-invasive treatment of patients with essential tremor who had not responded to medication. Essential tremor is the most common movement disorder, affecting more than 5 million people in the United States, and millions more worldwide. Hand tremor is the most common symptom and for these patients, performing everyday tasks can seem nearly impossible and greatly impacts on their quality of life.

About INSIGHTEC

INSIGHTEC is the world leader and innovator of MR-guided Focused Ultrasound (MRgFUS). The company's non-invasive platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world. For more information, please visit: http://www.insightec.com The Neuravive website for essential tremor patients is http://usa.essential-tremor.com .

Media Contact:
Michelle Barry
Red Lorry Yellow Lorry for INSIGHTEC
insightec@rlyl.com
+1-857-217-2886
Source: INSIGHTEC

Latest Press Release

Covaris Introduces the 96 oneTUBE-10 AFA Plate for Improved NGS Workflows

Today, Covaris Inc. announced the release of the 96 oneTUBE-10 AFA Plate, which enables scalable and simplified workflows by leveraging Covaris' gold standard focused-acoustic technology to meet rapidly increasing Next-Generation Sequencing (NGS) demands...

2018 Empire State Building Run-Up Lottery Registration Opens on November 14, 2017

Runners must enter by December 10 for a chance to participate in the 41st Annual Run-Up on Wednesday, February 7, 2018, at 8:00 p.m. Empire State Realty Trust, Inc. (NYSE: ESRT) today announced that lottery registration for the 2018 Empire State...

Alpinion Medical Systems Launches E-CUBE 8, the New Ultrasound Diagnostic System

One of South Korea's global medical device manufacturers, Alpinion Medical Systems introduced its new E-CUBE 8, the latest and last addition to the E-CUBE lineup. The E-CUBE 8 is a smart, reliable product that ensures high performance with outstanding...

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Blueprint for Change address Diabetes challenge , aligned with national NCD targets

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk...

Stryker announces publication of the DAWN(TM) Trial results in the New England Journal of Medicine

The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from...

Related Topics